Brief
African green monkeys show no memory loss a year after Alzheimer‑like brain changes
Researchers report that treated monkeys performed normally on memory tests 12 months after receiving synthetic amyloid‑beta, while spinal fluid showed immune protein changes.
By Felo News Desk · Published
A study published in Communications Biology reports that African green monkeys inoculated with synthetic amyloid‑beta plaques did not exhibit memory decline on a visual discrimination task a year after treatment, even though spinal fluid showed elevated immune‑system protein C3 and other vascular‑related proteins.
What happened
Five female African green monkeys received weekly injections of synthetic amyloid‑beta clusters for four weeks (12 total doses), while three control monkeys received a placebo solution. After the dosing period, the animals were tested on a shape‑recognition memory task, where they had to select a target shape from distractors after a brief pause. The treated monkeys performed at the same level as controls throughout the following year.
What the report adds
The Independent notes that spinal fluid collected 12 months after the final injection revealed higher levels of the complement protein C3 in the treated group, as well as significant differences in proteins linked to blood‑vessel function and clotting. The authors suggest these molecular changes indicate brain and nervous‑system alterations that are not reflected in overt behavioural symptoms.
What was said
"They share key physiological and biochemical traits with humans, including neuroanatomy, vascular structure, inflammatory responses, and lifespan," the study authors wrote, as quoted by the Independent.
How it came about
African green monkeys are frequently used as a non‑rodent model for Alzheimer’s disease because they naturally develop amyloid‑β plaques and tau tangles similar to humans. Earlier work showed that inoculating these monkeys with synthetic amyloid‑beta produces brain changes comparable to those seen in patients. This new research extends the observation period to a year, probing whether such changes persist and whether they translate into cognitive deficits.
Key facts
- Five female African green monkeys received 12 weekly injections of synthetic amyloid‑beta. (independent.co.uk)
- Treated monkeys showed no memory decline on a shape‑recognition test over 12 months. (independent.co.uk)
- Spinal fluid after a year showed elevated complement protein C3 and altered vascular‑related proteins in treated monkeys. (independent.co.uk)
Sources
- [1] independent.co.uk — originally reported as “Monkey that resists Alzheimer’s could be key to developing treatments”
